| Small Cell Lung Cancer with Mutation of Epidermal Growth Factor Receptor in Patients with Lung Adenocarcinoma Resistant to Gefitinib |
|
Jin Tak Yun1, Suk Young Park1, Young Jun Yang1, Ji Chan Park1, Jun Won Jung1, Jong Ok Kim2, Jung Uee Lee2 |
1Departments of Internal Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea
2Departments of Pathology, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea |
| Gefitinib에 내성을 보인 폐선암에서 발견된 Epidermal Growth Factor Receptor 돌연변이 양성인 소세포폐암 |
|
윤진탁1, 박석영1, 양영준1, 박지찬1, 정준원1, 김종옥2, 이정의2 |
1가톨릭대학교 의과대학 대전성모병원 내과
2가톨릭대학교 의과대학 대전성모병원 병리과 |
Correspondence:
Suk Young Park, Tel: +82-42-220-9821, Fax: +82-42-255-8663, Email: sypark1011@hotmail.com
|
|
Received: 10 February 2014 • Revised: 7 April 2014 • Accepted: 21 August 2014 |
|
|
| This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Abstract |
|
Most epidermal growth factor receptor (EGFR) gene mutations are detected in lung adenocarcinomas. In contrast, these mutations have rarely been reported in small cell lung cancer (SCLC). We herein report two cases of EGFR-mutant SCLC transformed from and combined with lung adenocarcinoma. In one case, SCLC appeared to be transformed from EGFR mutant 19-del adenocarcinoma when the patient became resistant to gefitinib. The other patient had combined EGFR-mutant 19-del SCLC and adenocarcinoma at the initial diagnosis, which was resistant to gefitinib at multiple sites. Further comparative molecular analyses of these histologically distinct tumors would provide useful information regarding the role of EGFR mutation in the pathogenesis of SCLC. In conclusion, despite the presence of the same EGFR mutation, gefitinib was not effective in treatment of SCLC. Therefore, confirmation of SCLC cell morphology may become an important means of predicting resistance to EGFR tyrosine kinase inhibitors in addition to common secondary genetic alterations. |
| Key Words:
Small cell lung carcinoma; Receptor, Epidermal growth factor; Mutation; Drug resistance |
| 주제어:
소세포폐암; 표피성장인자수용체; 돌연변이; 약물내성 |
|
PDF Links
Full text via DOI
Download Citation
